Krazati (adagrasib) — CareFirst (Caremark)
progressive ampullary adenocarcinoma
Initial criteria
- Requested medication will be used as a single agent
- Tumor or plasma specimen is positive for KRAS G12C mutation
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months